Access cutting-edge primary malignant peripheral nerve sheath tumors treatment through this early phase 1 clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Minneapolis location
Preparing your pre-screening questions…
Access primary malignant peripheral nerve sheath tumors specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary malignant peripheral nerve sheath tumors treatment provided free
Check if you qualify for this primary malignant peripheral nerve sheath tumors clinical trial in Minneapolis, MN
No-Cost Study Care
Local to Minneapolis
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a single center Phase 0 "window of opportunity" trial for the treatment of newly diagnosed, PRC2 deficient, primary malignant peripheral nerve sheath tumors (MPNSTs) with a short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for their specific tumor (typically localized radiation followed by surgical resection). Four to eight patients, 12 years of age or older and meeting the study's biomarker inclusion criteria, would be enrolled onto this trial. After voluntary written consent (assent with parent consent for minors) the patient undergoes MRI and PET imaging of the tumor and a needle biopsy to collect tumor is performed. Patients with histone H3K27 trimethylation deficient MPNST, as confirmed by immunohistochemistry, receive a single 28-day course of mirdametinib and vorinostat at standard oral dosing for each. At day 26, 27, or 28 the patient returns to clinic for a research visit repeating the baseline MRI and PET imaging and the needle biopsy for tumor tissue. This ends direct study participation. The patient goes on to the most appropriate standard of care treatment for their MPNST. Information about the subsequent standard of care treatment is collected for the purposes of this study.
Sponsor: University of Minnesota
Yes, this clinical trial (NCT06693284) has an active research site in Minneapolis, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for primary malignant peripheral nerve sheath tumors treatment options in Minneapolis, MN, this clinical trial (NCT06693284) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced primary malignant peripheral nerve sheath tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all primary malignant peripheral nerve sheath tumors clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Minneapolis — not just this study.
Browse Pulmonary Embolism Trials in Minneapolis →